ONLINE: 8th ESO-SIOP Europe Masterclass in Paediatric Oncology
Not eligible for ESCO credits
26.11.2021 - 28.11.2021
MASTERCLASS
Important Information
Due to the ongoing global pandemic Covid-19, ESO and SIOP Europe have taken the decision to convert the 8th ESO-SIOP Europe Masterclass in Paediatric Oncology that was scheduled on 27 November-2 December 2021, into virtual ON-LINE MASTERCLASS.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include pre-recorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
The online edition will be divided into two parts:
PART 1 (available from 15 October 2021)
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
PART 2 (26-27-28 November 2021)
Online live event with lectures/ live discussion and participants’ case presentations to be discussed with top level experts.
Description
Chairs: A. Attarbaschi, AT - B. Morland, UK - C. Stefan, RO/ZA
Host Chair: M. Dragomir, RO
The 8th ESO-SIOP Europe Masterclass in Paediatric Oncology is being organised as in person meeting, should this not be possible because of the pandemic the event will be held online. More information will follow.
ESO and SIOP Europe are pleased to announce the eighth Masterclass in Paediatric Oncology. This clinically-oriented educational programme has been designed for young paediatric oncologists, who wish to improve their skills in clinical management of common childhood tumours. It is designed to offer a unique learning experience, providing practice-oriented training and the teaching sessions will focus on the application of the most recent research findings to clinical practice.
LEARNING OBJECTIVES
• Improve knowledge in the field
• Improve skills in dealing with cancer problems as a whole
• Improve knowledge of current clinical practice and state-of-the-art treatment
MAIN TOPICS
• Bone tumours
• Central nervous system tumours
• Leukemia
• Lymphoma
• Neuroblastoma
• Rare tumours
• Soft-tissue sarcoma
• Wilms’ tumour
The Masterclass in Paediatric Oncology is an ESO-SIOP Europe joint event |
General information
ORGANISING SECRETARIAT
Alice Ciocchini
European School of Oncology (ESO)
Via Turati, 29
20121 Milan, Italy
ph +39 02 85464529
e-mail: aciocchini@eso.net
Applications:
Dolores Knupfer, dknupfer@eso.net, ph: +41 91 820 0952
CME ACCREDITATION AND CERTIFICATE
Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the application can be obtained from the organising secretariat.
Participants will receive their certificate of attendance via e-mail after on completion of the evaluation form.
ESCO CREDITS
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
Application
IDEAL MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• 2-4 years’ experience in paediatric oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
THE APPLICATION DEADLINE HAS PASSED (12 February 2020)